Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes

References

• PantopoulosKPorwalSKTartakoffADevireddyLMechanisms of mammalian iron homeostasisBiochemistry201251295705572422703180
   PubMed Web of Science ®Google Scholar
• AndrewsNCForging a field: the golden age of iron biologyBlood2008112221923018606887
   PubMed Web of Science ®Google Scholar
• No authors listedCommunity control of hereditary anaemias: memorandum from a WHO meetingBull World Health Organ198361163806601544
   PubMed Web of Science ®Google Scholar
• WeatherallDJGleggJBThe Thalassaemia Syndromes3rd edOxfordBlackwell Scientific Publications1981
   Google Scholar
• FederJNGnirkeAThomasWA novel MHC class I-like gene is mutated in patients with hereditary haemochromatosisNat Genet1996134339408
   Web of Science ®Google Scholar
• BartonJCEdwardsCQHemochromatosis: Genetics, Pathophysiology, Diagnosis and TreatmentCambridgeCambridge University Press2000
   Google Scholar
• HalliwellBGutteridgeJMFree radicals and antioxidant protection: mechanisms and significance in toxicology and diseaseHum Toxicol1988717133278973
   PubMedGoogle Scholar
• KontoghiorghesGJProspects for introducing deferiprone as potent pharmaceutical antioxidantFront Biosci (Elite Ed)2009116117819482634
   PubMedGoogle Scholar
• SingerSTVariable clinical phenotypes of α-thalassemia syndromesScientificWorldJournal2008961562519618088
   PubMedGoogle Scholar
• GalanelloRCaoARelationship between genotype and phenotype: thalassemia intermediaAnn NY Acad Sci19988503253339668554
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCModern treatment of thalassaemia intermediaBr J Haematol2007138329130417565568
   PubMed Web of Science ®Google Scholar
• PippardMJCallenderSTWarnerGTWeatherallDJIron absorption and loading in β-thalassaemia intermediaLancet19792814781982190918
   PubMed Web of Science ®Google Scholar
• PootrakulPKitcharoenKYansukonPThe effect of erythroid hyperplasia on iron balanceBlood1988714112411293355891
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJEracleousEEconomidesCKolnagouAAdvances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinationsCurr Med Chem200512232663268116305464
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJSpyrouAKolnagouAIron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorptionHemoglobin201034325126420524815
   PubMed Web of Science ®Google Scholar
• AessoposAKatiMFarmakisDHeart disease in thalassemia inter-media: a review of the underlying pathophysiologyHaematologica200792565866517488690
   PubMed Web of Science ®Google Scholar
• SonakulDPachareePWasiPFucharoenSCardiac pathology in 47 patients with β-thalassaemia/haemoglobin ESoutheast Asian J Trop Med Public Health19841545545636242076
   PubMedGoogle Scholar
• AessoposAFarmakisDTrompoukisCCardiac involvement in sickle β-thalassemiaAnn Hematol200988655756419107483
   PubMed Web of Science ®Google Scholar
• AessoposAFarmakisDKaragiorgaMCardiac involvement in thalassemia intermedia: a multicenter studyBlood200197113411341611369631
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCGaraniMCForniGLHepatocellular carcinoma in thalassaemia: an update of the Italian registryBr J Haematol2014167112112624992281
   PubMed Web of Science ®Google Scholar
• FragatouSTsourveloudisIManesisGIncidence of hepatocel-lular carcinoma in a thalassemia unitHemoglobin201034322122620524812
   PubMed Web of Science ®Google Scholar
• TaherATPorterJBViprakasitVApproaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxEur J Haematol201492652152624460655
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJA new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patientsHemoglobin200933533233819814679
   PubMed Web of Science ®Google Scholar
• KolnagouAKontoghiorgheCNKontoghiorghesGJTransition of thalassaemia and Friedreich ataxia from fatal to chronic diseasesWorld J Methodol20144419721825541601
   PubMedGoogle Scholar
• KontoghiorgheCNAndreouNConstantinouKKontoghiorghesGJWorld health dilemmas: orphan and rare diseases, orphan drugs and orphan patientsWorld J Methodol20144316318825332915
   PubMedGoogle Scholar
• KontoghiorghesGJKolnagouAMolecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelatorsCurr Med Chem200512232695270916305466
   PubMed Web of Science ®Google Scholar
• FucharoenSKetvichitPPootrakulPSiritanaratkulNPiankijagumAWasiPClinical manifestation of β-thalassemia/hemoglobin E diseaseJ Pediatr Hematol Oncol200022655255711132229
   PubMed Web of Science ®Google Scholar
• VichinskyEHemoglobin E syndromesHematology Am Soc Hematol Educ Program2007798318024613
   PubMedGoogle Scholar
• PantopoulosKFunction of the hemochromatosis protein HFE: lessons from animal modelsWorld J Gastroenterol200814456893690119058322
   PubMed Web of Science ®Google Scholar
• ByrnesVBarrettSRyanEIncreased duodenal DMT-1 expression and unchanged HFE mRNA levels in HFE-associated hereditary hemochromatosis and iron deficiencyBlood Cells Mol Dis200229325126012547214
   PubMed Web of Science ®Google Scholar
• MavrogeniSGotsisELadisVMagnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and β-thalassemia majorInt J Cardiovasc Imaging200824884985418581254
   PubMed Web of Science ®Google Scholar
• AuWYLamWWChuWWOrgan-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H diseaseAnn Hematol2009881094795019165482
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJChelators affecting iron absorption in miceArzneimittelforschung19904012133213352095129
   PubMed Web of Science ®Google Scholar
• ItaliaKYJijinaFJMerchantRResponse to hydroxyurea in β-thalassemia major and intermedia: experience in western IndiaClin Chim Acta20094071–2101519545554
   PubMed Web of Science ®Google Scholar
• SingerSTKuypersFAOlivieriNFFetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcomeBr J Haematol2005131337838816225658
   PubMed Web of Science ®Google Scholar
• PatrinosGPGrosveltFGPharmacogenomics and therapeutics of haemoglobinopathiesHemoglobin2008321–222923618275000
   PubMed Web of Science ®Google Scholar
• OlivieriNFFreedmanMHPerrineSPTrial of recombinant human erythropoietin: three patients with thalassemia intermediaBlood19928012325832601467532
   PubMed Web of Science ®Google Scholar
• AdekileADAzabAFAl-SharidaSIClinical and molecular characteristics of non-transfusion-dependent thalassemia in KuwaitHemoglobin201539532032626076396
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJNeocleousKKolnagouABenefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamineDrug Saf200326855358412825969
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJStructure/red blood cell permeability activity of iron(III) chelator complexesInorganica Chim Acta19881512101106
   Web of Science ®Google Scholar
• KontoghiorghesGJMayAUptake and intracellular distribution of iron from transferrin and chelators in erythroid cellsBiol Met199033–41831872073459
   PubMedGoogle Scholar
• ForsbeckKNilssonKKontoghiorghesGJVariation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexesEur J Haematol19873943183253691756
   PubMed Web of Science ®Google Scholar
• YamamotoRSWilliamsGMFrangelHHWeisburgerJH8-Hydroxyquinoline:chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamideToxicol Appl Pharmacol19711946876985132036
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJThe Design of Orally Active Iron Chelators for the Treatment of Thalassaemia [doctoral thesis]Colchester, UKUniversity of Essex1982
   Google Scholar
• HarveyRSReffittDMDoigLAFerric trimaltol corrects iron deficiency anaemia in patients intolerant of ironAliment Pharmacol Ther19981298458489768526
   PubMed Web of Science ®Google Scholar
• GascheCAhmadTTulassayZFerric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial programInflamm Bowel Dis201521357958825545376
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJDo we need more iron-chelating drugs?Lancet2003362938249549612927446
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJTransparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwideHemoglobin200832660861519065341
   PubMed Web of Science ®Google Scholar
• DresowBFischerRNielsenPGabbeEEPigaAEffect of oral iron chelator L1 on iron absorption in manAnn N Y Acad Sci19988504664689668586
   PubMed Web of Science ®Google Scholar
• BerkovitchMLivneALushkovGThe efficacy of oral defer-iprone in acute iron poisoningAm J Emerg Med2000181364010674529
   PubMed Web of Science ®Google Scholar
• DjaldettiMFishmanPNottiIBesslerHThe effect of tetracycline administration on iron absorption in miceBiomedicine19813551501527317563
   PubMedGoogle Scholar
• KonstantinouEPashalidisIKolnagouAKontoghiorghesGJInteractions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategiesHemoglobin201135323724621599436
   PubMed Web of Science ®Google Scholar
• ZurloMGDe StefanoPBorgna-PignattiCSurvival and causes of death in thalassaemia majorLancet19892865327302567801
   PubMed Web of Science ®Google Scholar
• ModellBKhanMDarlisonMSurvival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterLancet200035592202051205210885361
   PubMed Web of Science ®Google Scholar
• TelferPTWarburtonFChristouSImproved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiproneHaematologica200994121777177819815834
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJEthical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasiroxHemoglobin2008321–211518274978
   PubMed Web of Science ®Google Scholar
• CohenARIron chelation therapy: you gotta have heartBlood2010115122333233420339104
   PubMed Web of Science ®Google Scholar
• DézsiLVécseiLClinical implications of irregular ADMET properties with levodopa and other antiparkinson’s drugsExpert Opin Drug Metab Toxicol201410340942424437461
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJBartlettANSheppardLBarrJNorteyPOral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changesArzneimittelforschung199545165697893273
   PubMed Web of Science ®Google Scholar
• AessoposAKatiMFarmakisDPolonifiEDeftereosSTsironiMIntensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamineInt J Hematol200786321221517988985
   PubMed Web of Science ®Google Scholar
• MavrogeniSIGotsisEDMarkussisVT2 relaxation time study of iron overload in β-thalassemiaMAGMA1998617129794284
   PubMedGoogle Scholar
• AndersonLJHoldenSDavisBCardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overloadEur Heart J200122232171217911913479
   PubMed Web of Science ®Google Scholar
• KolnagouAYazmanDEconomidesCEracleousEKontoghiorghesGJUses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocolHemoglobin200933531232219814677
   PubMed Web of Science ®Google Scholar
• PennellDJT2* magnetic resonance and myocardial iron in thalassemiaAnn N Y Acad Sci2005105437337816339685
   PubMed Web of Science ®Google Scholar
• KolnagouAKleanthousMKontoghiorghesGJReduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapyEur J Haematol201085543043820662901
   PubMed Web of Science ®Google Scholar
• FarmakiKTzoumariIPappaCChouliarasGBerdoukasVNormalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia majorBr J Haematol2010148346647519912219
   PubMed Web of Science ®Google Scholar
• KolnagouAKontoghiorghesGJMaintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapyHemoglobin201034320420920524810
   PubMed Web of Science ®Google Scholar
• KolnagouAKleanthousMKontoghiorghesGJEfficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapyHemoglobin201135318619821599431
   PubMed Web of Science ®Google Scholar
• TannerMAGalanelloRDessiCCombined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJ Cardiovasc Magn Reson2008101218298856
   PubMed Web of Science ®Google Scholar
• WoodJCKangBPThompsonAThe effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron storesBlood2010116453754320421452
   PubMed Web of Science ®Google Scholar
• VlachakiEAgapidouASpanosGFive years of deferasirox therapy for cardiac iron in β-thalassemia majorHemoglobin201539529930426177199
   PubMed Web of Science ®Google Scholar
• MeerpohlJJAntesGRückerGDeferasirox for managing iron overload in people with thalassaemiaCochrane Database Syst Rev20122CD00747622336831
   PubMed Web of Science ®Google Scholar
• WasiPPootrakulPFucharoenSWinichagoonPWilairatPPromboonAThalassemia in southeast Asia: determination of different degrees of severity of anemia in thalassemiaAnn N Y Acad Sci19854451191263893274
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJKolnagouAPengCTShahSVAessoposASafety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseasesExpert Opin Drug Saf20109220120620059374
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationClinical review: Exjade (deferasirox, ICL-670)2005 Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4177B1_02_b.pdfAccessed December 1, 2015
   Google Scholar
• Exjade (deferasirox) tablets for oral suspension [prescribing information]East Hanover, NJNovartis Pharmaceutical Corporation2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdfAccessed December 1, 2015
   Google Scholar
• KontoghiorghesGJA record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?Expert Opin Drug Saf201312560560923688354
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJTurning a blind eye to deferasirox’s toxicity?Lancet201338198731183118423561999
   PubMed Web of Science ®Google Scholar
• BoelaertJRFenvesAZCoburnJWDeferoxamine therapy and mucormycosis in dialysis patients: report of an international registryAm J Kidney Dis19911866606671962650
   PubMed Web of Science ®Google Scholar
• OrtonRBde VeberLLSulhHMOcular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapyCan J Ophthalmol19852041531564052864
   PubMed Web of Science ®Google Scholar
• CasesAKellyJSabaterFOcular and auditory toxicity in hemodialyzed patients receiving desferrioxamineNephron199056119232234245
   PubMed Web of Science ®Google Scholar
• BoddaertNSangKHRötigASelective iron chelation in Friedreich ataxia: biologic and clinical implicationsBlood2007110140140817379741
   PubMed Web of Science ®Google Scholar
• RajapurkarMMHegdeUBhattacharyaAAlamMGShahSVEffect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular diseaseToxicol Mech Methods201323151022978744
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPigaADe SanctisVTrictaFSafety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood200310251583158712763939
   PubMed Web of Science ®Google Scholar
• PootrakulPVongsmasaVLaongpanichPWasiPSerum ferritin levels in thalassemias and the effect of splenectomyActa Haematol19816642442506800190
   PubMed Web of Science ®Google Scholar
• CossuPToccafondiCVardeuFIron overload and desferriox-amine chelation therapy in β-thalassemia intermediaEur J Pediatr198113732672717318837
   PubMed Web of Science ®Google Scholar
• NielsenPFischerRBuggischPJanka-SchaubGEffective treatment of hereditary haemochromatosis with desferrioxamine in selected casesBr J Haematol2003123595295314632789
   PubMed Web of Science ®Google Scholar
• PootrakulPSirankaprachaPSankoteJClinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in ThailandBr J Haematol2003122230531012846901
   PubMed Web of Science ®Google Scholar
• ChanJCChimCSOoiCGUse of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H diseaseBr J Haematol2006133219820516611312
   PubMed Web of Science ®Google Scholar
• OlivieriNFKorenGMatsuiDReduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermediaBlood19927910274127481586721
   PubMed Web of Science ®Google Scholar
• CalvarusoGVitranoADi MaggioRDeferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trialAm J Hematol201590763463825809173
   PubMed Web of Science ®Google Scholar
• FabioGMinonzioFDelbiniPBianchiACappelliniMDReversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemo-chromatosis (JH)Blood2007109136236416960153
   PubMed Web of Science ®Google Scholar
• TaherATPorterJViprakasitVDeferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyBlood2012120597097722589472
   PubMed Web of Science ®Google Scholar
• KarimiMArandiNHaghpanahSEfficacy of deferasirox (Exjade®) in modulation of iron overload in patients with β-thalassemia intermediaHemoglobin201539532732926114738
   PubMed Web of Science ®Google Scholar
• Al-KhaboriMBhandariSAl-HuneiniMAl-FarsiKPanjwaniVDaarSSide effects of deferasirox iron chelation in patients with beta thalassemia major or intermediaOman Med J201328212112423599881
   PubMedGoogle Scholar
• DeeCMCheukDKHaSYChiangAKChanGCIncidence of deferasirox-associated renal tubular dysfunction in children and young adults with β-thalassaemiaBr J Haematol2014167343443624989901
   PubMed Web of Science ®Google Scholar
• ChuangGTTsaiIJTsauYKLuMYTransfusion-dependent thalas-saemic patients with renal Fanconi syndrome due to deferasirox useNephrology (Carlton)2015201293193526016559
   PubMed Web of Science ®Google Scholar
• NaderiMSadeghi-BojdSValeshabadAKA prospective study of tubular dysfunction in pediatric patients with β-thalassemia major receiving deferasiroxPediatr Hematol Oncol201330874875424134694
   PubMed Web of Science ®Google Scholar
• TeawtrakulNChansungKSirijerachaiCWanitpongpunCThepsuthammaratKThe impact and disease burden of thalassemia in Thailand: a population-based study in 2010J Med Assoc Thai201295Suppl 7S211S21623130457
   PubMedGoogle Scholar
• ViprakasitVNuchprayoonIChuansumritADeferiprone(GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from ThailandAm J Hematol201388425126023460233
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJFuture chelation monotherapy and combination therapy strategies in thalassemia and other conditions: comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymersHemoglobin200630232994716798657
   PubMed Web of Science ®Google Scholar
• TotadriSBansalDBhatiaPAttriSVTrehanAMarwahaRKThe deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: a prospective, single center, open-label studyPediatr Blood Cancer20156291592159625820920
   PubMed Web of Science ®Google Scholar
• CassinerioEOrofinoNRoghiACombination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patientsBlood Cells Mol Dis201453316416724846580
   PubMed Web of Science ®Google Scholar
• ElalfyMSAdlyAMWaliYTonySSamirAElhenawyYIEfficacy and safety of a novel combination of two oral chelators deferasirox/ deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patientsEur J Haematol201595541142025600572
   PubMed Web of Science ®Google Scholar
• KolnagouAMichaelidesYKontoghiorgheCNKontoghiorghesGJThe importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patientsToxicol Mech Methods2013231344123039902
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJGoddardJGBartlettANSheppardLPharma-cokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-oneClin Pharmacol Ther19904832552612401124
   PubMed Web of Science ®Google Scholar
• WaldmeierFBruinGJGlaenzelUPharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady stateDrug Metab Dispos201038580881620097723
   PubMed Web of Science ®Google Scholar
• CaoHPharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitorsHematology20049322323315204104
   PubMedGoogle Scholar
• RuchalaPNemethEThe pathophysiology and pharmacology of hepcidinTrends Pharmacol Sci201435315516124552640
   PubMed Web of Science ®Google Scholar
• ArezesJNemethEHepcidin and iron disorders: new biology and clinical approachesInt J Lab Hematol201537Suppl 1929825976966
   PubMed Web of Science ®Google Scholar
• KontoghiorghesGJBarrJNorteyPSheppardLSelection of a new generation of orally active α-ketohydroxypyridine iron chelators intended for use in the treatment of iron overloadAm J Hematol19934243403498493983
   PubMed Web of Science ®Google Scholar
• KontoghiorgheCNKolnagouAKontoghiorghesGJPotential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metalsExpert Opin Investig Drugs2013225591618
   PubMed Web of Science ®Google Scholar
• VreugdenhilGSwaakAJde Jeu-JaspersCvan EijkHGCorrelation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritisAnn Rheum Dis199049119569572256752
   PubMed Web of Science ®Google Scholar
• EvansRWSharmaMOgwangWPatelKJBartlettANKon-toghiorghesGJThe effect of α-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivoDrugs Today199228Suppl A923
   Google Scholar
• SmeetsMEVreugdenhilGHoldrinetRSImprovement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosisAm J Hematol19965132432448619408
   PubMed Web of Science ®Google Scholar
• ChangYHShawCFWuKHHsiehKHSuYNLuPJTreatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patientHemoglobin200933534635119814681
   PubMed Web of Science ®Google Scholar
• VreugdenhilGSwaakAJKontoghiorghesGJvan EijkHGEfficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patientsLancet198928676139813992574342
   PubMed Web of Science ®Google Scholar
• MostertLJVan DorstJAKosterJFVan EijkHGKontoghiorghesGJFree radical and cytotoxic effects of chelators and their iron complexes in the hepatocyteFree Radic Res Commun1987363793883508452
   PubMedGoogle Scholar
• BrockJHLicéagaJArthurHMKontoghiorghesGJEffect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophagesAm J Hematol199034121252327400
   PubMed Web of Science ®Google Scholar